Corporate | 25 October 2007 11:24
STRATEC Biomedical Systems AG / Alliance
Release of a Corporate News, transmitted by DGAP - a company of EquityStory
AG.
The issuer / publisher is solely responsible for the content of this announcement.
----------------------------------------------------------------------
STRATEC and Future Diagnostics to cooperate in developing system solutions
Birkenfeld, October 25, 2007
On October 24, 2007, STRATEC Biomedical Systems AG, Birkenfeld, Germany,
specialized in the design and manufacture of automatic laboratory analyzer
systems in high quantities for large customers, signed an agreement with
Future Diagnostics B.V., Wijchen, The Netherlands, concerning the joint
development of new system solutions. Since its establishment in 1997,
Future Diagnostics (http://www.future-diagnostics.nl) has developed more
than 100 different tests, especially immunoassays, for market leaders and
global players in the diagnostics industry.
In the interests of their OEM customers, the two companies will contribute
to the cooperation their expertise in developing and producing reagents and
analyzer systems in order to develop system solutions together based on
common specifications. The jointly developed systems are to be offered to
OEM customers for marketing.
Cooperation has initially been agreed for three years. Further details
concerning the cooperation are subject to the confidentiality agreement
signed between the two parties.
'STRATEC and Future Diagnostics have a longstanding history in common. The
companies have virtually identical customer bases. While our cooperation
partner Future Diagnostics develops reagents and tests for customers based
on proprietary expertise, STRATEC supplies these customers with analyzer
systems developed under its own responsibility. Together, the two
components – reagents and analyzer systems – form new system solutions, for
example to investigate infection parameters (such as hepatitis and HIV) in
human blood. These systems can then be marketed around the world by our
mutual customers. More than one third of the tests developed by Future
Diagnostics for several customers are routinely used in analyzer systems
developed and produced by STRATEC', commented Hermann Leistner, Chairman of
the Board of Management of STRATEC Biomedical Systems AG.
With the cooperation, STRATEC and Future Diagnostics intend to offer their
customers complete system solutions from a single source in future, such as
those used for near-patient testing, for example the rapid, reliable and
routine-laboratory-compatible performance of cardiovascular tests for
coronary and apoplectic parameters. This possibility of outsourcing
analyzer system and reagent development will provide the two companies’
mutual customers with decisive added value.
About STRATEC
STRATEC Biomedical Systems AG (http://www.stratec-biomedical.de) designs
and manufactures fully automated systems for its partners in the fields of
clinical diagnostics and biotechnology. These partners market such systems,
in general together with their own reagents, to laboratories, blood banks
and research institutes around the world. The company develops its products
on the basis of its own patented technologies. Shares in the company (ISIN:
DE0007289001) are traded in the Prime Standard segment of the Frankfurt
Stock Exchange and on other exchanges.
The STRATEC Group consists of the publicly listed parent company STRATEC
Biomedical Systems AG and its subsidiaries STRATEC Biomedical Inc., STRATEC
NewGen GmbH, Robion AG and Sanguin International Ltd., as well as Sanguin
International Inc., a subsidiary of Sanguin International Ltd.
Further information can be obtained from:
STRATEC Biomedical Systems AG
André Loy, Investor Relations
Gewerbestrasse 37, 75217 Birkenfeld
Germany
Tel: +49 (0)7082 7916 190
Fax: +49 (0)7082 7916 999
E-mail: ir@stratec-biomedical.de
25.10.2007 Financial News transmitted by DGAP
----------------------------------------------------------------------
Language: English
Issuer: STRATEC Biomedical Systems AG
Gewerbestraße 37
75217 Birkenfeld
Deutschland
Phone: +49 (0)7082 7916 0
Fax: +49 (0)7082 7916 999
E-mail: info@stratec-biomedical.de
Internet: www.stratec-biomedical.de
ISIN: DE0007289001
WKN: 728900
Listed: Geregelter Markt in Frankfurt (Prime Standard); Freiverkehr
in Stuttgart, München, Düsseldorf
End of News DGAP News-Service
---------------------------------------------------------------------------